Comparison of three alternatives for the management of moderate asthma in children aged 6-11 years: a cost-utility analysis.

Jefferson Antonio BuendiaErika Fernanda LindarteDiana Guerrero Patiño

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2022)

Our study showed that SMART was more cost-effective than fixed combination and fixed-dose budesonide. These findings complement and support the GINA 2021 and National Asthma Education and Prevention Program asthma guideline recommendations for use of inhaled corticosteroids-formoterol in children 6-11 years old with persistent asthma.

Keyphrases

chronic obstructive pulmonary disease
lung function
allergic rhinitis
quality improvement
cystic fibrosis
healthcare
young adults